Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas. By positional cloning of ampli®ed genes by yeast arti®cial chromosome-mediated cDNA capture using magnetic beads, we have identi®ed three candidate genes (COAS1, -2 and -3) in the ampli®ed region in sarcomas. COAS1 and -2 showed higher ampli®cation levels than COAS3. Most notably, ampli®cation was very common in osteosarcomas, where in particular COAS2 was highly expressed. COAS1 has multiple repeats and shows no homology to previously described genes, whereas COAS2 is a novel member of the cyclosporin-binding peptidylprolyl isomerase family, very similar to cyclophilin A. COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistant tumours. Although COAS2 was generally more ampli®ed than COAS1, it was not expressed in well-dierentiated liposarcomas, where ampli®cation of this region is very common. All three genes were found to be ampli®ed and over-expressed also in breast carcinomas. The complex nature of the 1q21-23 amplicons and close proximity of the genes make unequivocal determination of the gene responsible dicult. Quite likely, the dierent genes may give selective advantages to dierent subsets of tumours.
Introduction
Gains or ampli®cations along the long arm of chromosome 1 are found in leukaemias and solid tumours, and are among the most common chromosomal anomalies in human neoplasia (Alers et al., 2000; Kiechle et al., 2000; Mairal et al., 2000; Malamou-Mitsi et al., 1999; Matthews et al., 2000; Weber et al., 2000a,b) . Local gain or high-level ampli®cation aecting mainly 1q21-q23 has been reported for breast cancer cell lines (1q21-q32) (Larramendy et al., 2000) , hepatocellular carcinomas (1q12-q22) (Guan et al., 2000) , retinoblastomas (1q21) (Mairal et al., 2000) and sarcomas (Forus et al., 1995a,b; Szymanska et al., 1997; Tarkkanen et al., 1995) , and is of particular interest since they appear more frequently in aggressive tumours with metastatic potential (Alers et al., 2000; Gronwald et al., 1997; Tarkkanen et al., 1999) and resistance to chemotherapy (Kudoh et al., 1999) .
We have previously de®ned the most frequently ampli®ed part of 1q21 using FISH and molecular analyses (Forus et al., 1998) . This region is localized between the large heterochromatic segment 1q12 and the Epidermal Dierentiation Complex (EDC) (Mischke et al., 1996) . Using available probes we identi®ed a highly and frequently ampli®ed segment covered by a yeast arti®cial chromosome (YAC) of 1 Mb. Other markers in the region showed mainly low-level ampli®cation and considerable heterogeneity. In order to identify possible target genes we have used this YAC for direct cDNA selection to capture transcripts from an osteosarcoma cell line with high-level ampli®cation of 1q21-q22.
made from the osteosarcoma cell line Saos-2. cDNAs that hybridized to the YAC (or yeast) DNA were isolated using avidin-coated magnetic beads, and the selected population of cDNAs was used to generate a library. Twenty authentic clones were identi®ed based on the absence of hybridization to irrelevant YACs, yeast, or total human DNA, and positive hybridization to YAC 789f2.
Characterization of candidate cDNAs
Sequence analysis revealed that several of the clones were redundant, and represented three candidate genes, none of which have been described previously. The genes were designated COAS1, COAS2 and COAS3 (for Chromosome One Ampli®ed Sequence). Localization to 1q21 was con®rmed by FISH analysis, although minor signals could also be observed in 1p36 with COAS1 cDNA and COAS2 cosmid ( Figure 1a ). This most likely is due to the known duplication of this region (Hardas et al., 1994) , also detected with YAC 789f2. Preliminary analysis showed all three candidates to be ampli®ed and over-expressed in sarcoma samples with 1q21 ampli®cation.
BLAST analysis (Altschul et al., 1997) showed that COAS1 was identical to segments of partially characterized cDNA sequences, as well as numerous ESTs. One of these was the cDNA KIAA1245, corresponding to a 6.9 kb cDNA isolated from brain tissue, with a predicted open reading frame (ORF) of 892 amino acids. This sequence was also present in PAC RPCI-328E19, partly corresponding to a hypothetical gene predicted as 22 exons, giving rise to a transcript of 3689 bp and an ORF of 921 amino acids. However, no functional leads could be found from the sequence.
Further analysis of the COAS1 and KIAA1245 sequences revealed the presence of a repeat unit of 866 bases within the 3' untranslated region (UTR). This repeat is unique to COAS1, which contains three complete copies, two with 100% identity and the third diering in only one base pair. A truncated fourth copy was found 5' to the others. However, each of these 866 repeat are spliced together from separate exons containing four smaller subrepeats of 175 bp, with dierent degrees of identity ranging from 100 to 85%. Further analysis revealed that such 175 bp repeats are found both in 1q21 and 1p35-ptel, most likely contributing to the FISH signal observed in 1p36 ( Figure 1a ). In addition, sequences with 98% similarity to the 175 bp subrepeats were also found in two PACs localized to chromosomes 3 and 6.
The complete coding sequence of COAS2 was found in one exon, and the corresponding sequence was cloned from YAC 789f4. There was discrepancy between the sequence of the region from the Sanger centre and from Celera, and three independent clones were sequenced from each of two independent PCR reactions to verify the sequence of the YAC-derived gene. The predicted ORF showed 84% amino acid identity to cyclophilin A (PPIA, chromosome 7p13), belonging to the cyclophilin family of peptidyl-prolyl cis-trans isomerases (Haendler et al., 1987) . The similarity to other known cyclophilins was less; 66% to CycF, 61% to CycE, 59% to CycC, 55% to CycB, and 53% to CycD. Figure 2 illustrates the similarities at the amino acid level of COAS2 with other members of the cyclophilin family. The active site of human cyclophilin A is formed by the residues R55, I57, F60, Q63, A101, N102, Q111, F113, L122, H126 and R148 (Spitzfaden et al., 1992) , all perfectly conserved in COAS2. In addition, the cis-proline binding pocket formed by the amino acids F60, M61, F13 and L122 is also conserved.
Although the initial captured COAS3 cDNA showed homology to Pro®lin 1, localized to chromosome 17p13.3, only a small region of homology to Pro®lin was found in the available genomic sequence from 1q21. A larger COAS3 cDNA of 1338 bases (DKFZp418G1157) was isolated from a mammary gland library (DKFZ Lib. No. 418) . Sequence analysis con®rmed its location within the genomic clone RPCI-565E6, in 1q21, but the similarity to Pro®lin 1 was only in the 5' end. The longest predicted open reading frame showed no homology to the Pro®lin protein family or any other described amino acid sequence.
Physical mapping of the clones
To further characterize the order and precise location of COAS1, -2 and -3, the isolated cDNA clones were hybridized to ®lters containing fragmented YACs from a 6 Mb contig covering the region of interest (Lioumi et al., 1998) . The three genes were situated between the genetic markers D1S442 and WI7969. COAS3 was the most centromeric sequence and COAS2 the most distal ( Figure 1b) .
Searches of the High Throughput Genomic Sequence Database showed that COAS1 and COAS2 were located approximately 60 kb apart in the genomic clone RPCI-328E19, oriented head to tail. RPCI-328E19 overlaps with RPCI-565E6, containing COAS3, placing COAS3 about 11 kb centromeric from COAS1 (Figure 1b) . The PACs containing COAS1, -2 and -3 were reported by the Sanger Centre to be localized in 1q12-22.2, thus con®rming our results. Figure 1 shows the chromosomal localization of the genes, as well as a map of the genomic region.
Analysis of amplification in clinical samples
Gene copy numbers were determined by FISH to interphase nuclei from selected soft tissue sarcomas, osteosarcoma xenografts, and cell lines with ampli®ca-tion of 1q21-q22 (Forus et al., 1998 (Forus et al., , 1995b A Forus et al., unpublished) , as well as additional unselected osteosarcomas and breast carcinomas.
There was considerable heterogeneity in copy numbers in the clinical samples, as observed by others (Ambros et al., 2001; Forus et al., 1998) . However, with the exception of MFH25, used as a negative control because it lacks detectable 1q21-q23 ampli®ca-tion, all the samples, even those from unselected cases, showed increased copy numbers of at least one of the three candidate genes (Figure 3a ,b). In most of the soft tissue sarcomas with 1q ampli®cation, a relatively large fraction of nuclei had high-level ampli®cation of all three genes, but COAS1 and COAS2 were present in higher copy numbers than COAS3 (Figure 3b ). Five of the nine samples had high-level ampli®cation of at least one of the genes in more than 40% of the nuclei. In three osteosarcoma cell lines, almost all nuclei showed high-level ampli®cation for all three genes. In the OS patient and xenograft panel, a majority of the samples had high-level ampli®cation of COAS1 and/or COAS2 in more than 40% of the nuclei, whereas COAS3 in general was moderately ampli®ed.
In the breast tumours and cell lines, the three genes showed mostly moderate ampli®cation levels, but some samples had high-level ampli®cation, although only in 20 ± 37% of the nuclei. In these cases COAS2 and COAS3 showed higher copy numbers than COAS1 (Figure 3b ).
Expression studies
The expression levels of the three genes were analysed in clinical samples and cell lines from sarcomas, mammary carcinomas and 15 normal tissues ( Figure  4 ). The COAS1 transcript was expressed in most of the normal tissues tested, with highest levels in brain, ovary, mammary gland, skin and adipose tissue ( Figure  4 ). Due to the large size of the transcript, the signals were somewhat degraded and spread out. Similarly, COAS2 was expressed in the majority of normal tissues tested, with the highest transcript levels detected in brain, and the lowest in skeletal muscle (Figure 4 ). COAS3 was also expressed in normal tissue, with high levels in adipose tissue, intestine, and spleen ( Figure 4 ). Chromosomal localization and physical mapping of the COAS1, -2, and -3. (a) Biotin labelled COAS1 was hybridized to normal metaphase chromosomes, ampli®ed by tyramid signal ampli®cation (TSA) and detected by FITC conjugated streptavidin (green). A strong signal was observed on 1q21 (arrow head) and a weaker signal on 1p36 (open arrow head). Cosmid ICRFc112N1180 and ICRFc112I1772 speci®c for COAS2 and COAS3 respectively, were labelled with biotin and hybridized to metaphase chromosomes. Cosmids were detected using Cy3 (red) conjugated avidin. A clear signal was observed on 1q21 (arrow head) and for ICRFc112N1180 an additional weak signal on 1p36 was seen (open arrow head). (b) A physical map of the COAS1, -2 and -3 was designed by hybridization of the dierent genes to a ®lter of fragmented YACs from a 6 Mb contig covering the region of interest and sequence analysis. PAC RPCI565E6 and RPCI 328E19 show an overlap of approximately 2.2 kb with 99% of identity. A third PAC, RP4-646P11, partially overlapped the two previously described PACs. COAS3 was the most centromeric gene and COAS2 the most telomeric. The orientation of transcription is shown with an arrow. All the genes were located between the genetic markers D1S3621 and WI7969, proximal to the epidermal dierentiation complex (EDC) COAS1 was expressed in most of the tumour samples and cell lines tested, showing very high expression levels in the osteosarcomas that had highlevel ampli®cation of the gene (Figure 4) . In soft tissue sarcomas, expression levels were generally moderate, but in several cases much higher than in normal tissue (compare with samples from mammary gland and adipose tissue on the same ®lter). Two of the mammary carcinomas, Ma201 and Ma215, showed very high expression levels of the gene, whereas mRNA levels in the remaining samples were moderate ( Figure  4) .
Although COAS2 was ampli®ed in all the liposarcomas (Figure 3b ), elevated expression was detected only in pleomorphic and undierentiated liposarcomas (LS3, LS28x and LS42, data not shown for LS28x and LS42), being almost undetectable in well-dierentiated cases (Figure 4) . The gene showed relatively high expression levels in the OS samples with ampli®cation, and in four additional OS samples (OS1x, OS2x, OS11x and OS12x) that were not included in the FISH analyses. All the osteosarcoma cell lines showed much higher expression levels of COAS2 than the normal tissues. COAS2 was expressed in all the mammary carcinomas and cell lines, and expression levels were four to seven times higher in the cell lines than in normal mammary gland (Figure 4) .
COAS3 was expressed in all mammary carcinomas and cell lines, and most of the soft-tissue sarcomas, but generally at low levels in the OS samples and cell lines (Figure 4 ).
Discussion
Using a YAC-based gene capture technique, we have isolated and characterized three new ampli®ed genes in 1q21. The COAS1, -2 and -3 genes were highly expressed in both sarcomas and breast cancer. They show recurrently high ampli®cation levels in sarcomas and moderate in breast cancer, and represent the ®rst candidate target genes for this very common ampli®cation. Because of the clustering of the genes within about 70 kb, ampli®cation patterns are very similar, although COAS3, which is very close to COAS1, is in most cases less ampli®ed than the other two. Based on the ampli®cation frequencies and expression pattern, COAS1, which has no homology to any known gene, and COAS2, which shows high homology to cyclophilin A, are the most interesting candidates.
The very large COAS1 mRNA contains several unique almost perfect repeats at the 3' end. However, due to the lack of structural or functional data, we cannot suggest a role for this gene in tumour biology. COAS1 is expressed in most of the tumour samples, also in the almost benign well-dierentiated liposarcomas (WDLPS), suggesting a more general function in tumorigenesis, rather than being a marker for tumour progression.
For COAS2, on the other hand, the homology to cyclophilins suggests many possible roles. At least eight dierent human cyclophilins have been described, as well as a number of pseudogenes, one of which has been shown to be ampli®ed in breast cancer (Collins et al., 1998) . Cyclophilins are a ubiquitous group of peptidyl-prolyl cis-trans isomeres (PPIs) that are highly conserved during evolution (Ozaki et al., 1996) , and bind the immunosuppressive drug Cyclosporin A (CsA) with high anity (Liu et al., 1991) . PPIs may modulate the activity of other proteins through the direct structural eect of peptide bond isomerization, but also through reciprocal modulation of protein phosphorylation (Lu, 2000) .
Increased cyclophilin activity in tumours has previously been reported (Koletsky et al., 1986) , and Rey et al. (1999) have recently shown an increase in cyclophilin A expression during the transition of human keratinocytes from an immortal to a malignant phenotype. Another novel member of the cyclophilin family (PPIE) was ampli®ed in small cell lung cancer cell lines with L-myc ampli®cation (Kim et al., 1998) . Furthermore, cyclophilin A has been suggested to be secreted and have growth factor activity under oxidative stress (Jin et al., 2000) , and exposure of hepatocytes to peroxisome proliferation inducers upregulates cyclophilin A expression (Corton et al., 1998) .
In addition to the cyclophilins, two other families of PPIs have been described, the FK506-binding proteins (FKBPs) (Harding et al., 1989; Siekierka et al., 1989) and parvulins (Rahfeld et al., 1994) , both structurally unrelated to the cyclophilins. In spite of this, it has been shown that overexpression of cyclophilin A can rescue a lethal parvulin mutant in yeast (ArevaloRodriguez et al., 2000) . Thus, ampli®cation and overexpression of one PPI might also aect pathways regulated by structurally unrelated PPIs.
Other PPIs have functions that are highly relevant to the phenotypes of tumours with 1q ampli®cation. cFKBP/SMAP is important in smooth muscle cell dierentiation (Fukuda et al., 1998) , and FKBP51 is highly expressed during the clonal expansion phase of adipocyte dierentiation (Yeh et al., 1995) , implicating these proteins in mesenchymal dierentiation. The metazoan parvulin, Pin1, is involved in chromatin condensation and regulation of the G2/M transition (Lu et al., 1996) . Furthermore, FKBP12 activity has been shown to be important for multidrug resistance through the P-glycoprotein pathway in yeast (Hemenway and Heitman, 1996) , perhaps relevant to the poor chemotherapy response associated with 1q21-22 ampli®cation in ovarian carcinomas (Kudoh et al., 1999) . In this context it is notable that the osteosarcomas with their very frequent ampli®cation and over-expression of COAS2 routinely receive preoperative chemotherapy.
It is striking that although COAS2 is the most ampli®ed gene also in liposarcomas, it is hardly expressed in the well-dierentiated liposarcomas (WDLPS), as opposed to high-grade samples. It thus seems likely that in WDLPS, COAS2 is less important, and COAS1 is a more likely target gene. This resembles the situation observed for 12q13-15 (Berner et al., 1996) , where ampli®cation always includes CDK4 and is associated with metastasis and tumour progression in osteosarcomas. In the less malignant WDLPS, on the other hand, ampli®cation is associated with complex marker ring or rod chromosomes that always include the MDM2 gene. These marker chromosomes frequently also contain segments from 1q (Pedeutour et al., 1999) , and in several cases transcripts fusing the HMGIC gene in 12q15 to sequences from 1q have been found (MezaZepeda et al., 2001) .
In general, expression of COAS2 was associated with clinical behaviour in our preliminary analysis of a small number of cases. In addition to the correlation mentioned for liposarcomas, the only osteosarcoma analysed that did not express any of the COAS genes (OS7x) was from one of two patients who did not develop metastasis, but showed complete remission (Table 1) . Interestingly, ®ve out of ®ve xenografts with expression of the gene respond poorly to chemotherapy using methotrexate, cisplatin or ifosfamide, and two of these were resistant to all three drugs (K Breistùl, unpublished).
COAS1 and -2 represent the ®rst likely target genes for the 1q21 ampli®cations. Further studies need to be done to determine their possible role in the development or progression of dierent cancer subtypes. Figure 4 Expression analysis. Expression of COAS1, -2 and -3 in tumour and normal tissue. COAS1, -2 and -3 were sequentially hybridized to three dierent Northern blots (a,b,c), containing total RNA from soft tissue sarcomas, breast carcinomas, and cell lines, osteosarcoma xenografts and cell lines, and a panel of dierent normal tissues. Hybridization to an 18 S rRNA oligonucleotide probe is shown as loading control. LP, lipoma; LS, liposarcoma; MFH, malignant ®brous histiocytoma; OS, osteosarcoma; Ma, mammary carcinomas; cl, cell line; sux`x', xenograft
Materials and methods

Specimens
Eight soft tissue sarcomas of various subtypes, 10 osteosarcoma samples or xenografts, four osteosarcoma cell lines, Saos-2 (ATCC, HTB-85), IOR/MOS, IOR/OS14 and IOR/ OS15 (established at the Istituti Ortopedici Rizzoli, Bologna, Italy), eight ductal breast carcinomas and two breast cancer cell lines, Ma11 and SK-BR-3 (ATCC, HTB-30), were analysed by FISH. All soft-tissue sarcomas, except for one (MFH25), as well as the OS cell lines and two of the xenografts (OS4x and OS9x) had previously identi®ed ampli®cation of 1q21-q22 (Forus et al., 1995a (Forus et al., ,b, 1998 A Forus et al., unpublished) . Since RNA was not available for all the OS samples analysed by FISH, six additional OS samples and the OHS cell line were included in the expression analyses. OHS was established from the same patient sample as OS5x. Clinical specimens were collected immediately after surgery, cut into small pieces, frozen in liquid nitrogen and stored at 7708C until use. All tumours were classi®ed according to the WHO International Histological Classi®ca-tion of Tumours.
Cloning and characterization of cDNAs
Poly(A)
+ RNA was isolated from 75 mg of total RNA from Saos-2 cells, using the mRNA direct kit (Dynal, Norway) as described by the supplier. One microgram of poly(A) + RNA was used as substrate for the ®rst and second strand cDNA synthesis, using the Marathon cDNA ampli®cation kit (Clontech, Palo Alto, CA, USA). Adapters were ligated to the cDNAs, and ampli®cation of the library was performed by touchdown Polymerase Chain Reaction (PCR). An aliquot of the diluted linkered cDNAs was ampli®ed using adapter-speci®c primers and the Advantage cDNA polymerase mix (Clontech, Palo Alto, CA, USA), according to the suppliers manual. Direct cDNA selection was performed as described previously (Lovett et al., 1991) with some modi®cations. Brie¯y, 6 mg of the cDNA library was mixed with 10 mg of Cot-1 DNA (Gibco ± BRL), and precipitated with ethanol. The DNA pellet was washed and resuspended in 100 ml of prehybridization solution (26SSC, 0.1% SDS, 16Denhardt), denatured for 5 min at 958C and prehybridized at 688C for 4 h.
Total yeast DNA containing CEPH megaYAC 789f2 was puri®ed by standard procedures, and labelled with biotin 14-dATP by nick translation at 168C (Bionick, Gibco ± BRL). Two micrograms of biotinylated YAC DNA was mixed with 30 mg of total yeast DNA, ethanol precipitated and washed and pre-hybridized as described for the cDNA. Thereafter, cDNA and YAC DNA was pooled, precipitated with ethanol, dissolved in 100 ml of hybridization solution (66SSC, 0.1% SDS, 16Denhardt), and hybridized at 688C for 48 h. Two milligrams of streptavidin-coated magnetic beads (Roche Molecular Biochemicals) were washed three times with 16 washing/binding buer (0.16SSC, 0.1% SDS), resuspended in 26 binding buer and added to the YAC/cDNA hybridization mix. The YAC/cDNA complex was allowed to anneal to the streptavidine-coated beads for 30 min at room temperature, and the bead/DNA complex was collected using a magnet. Beads were resuspended and washed 26 15 min at RT and then 36 at 658C, in 0.16SSC, 0.1% SDS. Selected cDNAs were eluted in 100 ml of dH 2 O by 10 min incubation at 808C and recaptured as a bead/genomic DNA complex. Ampli®cation of the captured cDNAs was adapter-speci®c as previously described. The selected and ampli®ed clones correspond to the Saos-2 selected library described later.
Ampli®ed cDNAs were puri®ed and incubated in 16 AmpliTaq Buer in the presence of AmpliTaq Gold (Perkin Elmer Co), 2 mM Mg 2+ and dATP for 30 min at 728C. An aliquot of the adenosine extended PCR products was ligated to the pCR 2.1 vector (Invitrogen, The Netherlands) as described by the supplier. Two microliters of the ligation mix was used to transform chemically competent cells (TOP10, Invitrogen) by standard heat shock procedure. Transformed cells were plated in LB ampicillin plates containing IPTG and X-Gal.
DNA from the 96 selected clones was isolated by standard miniprep protocols (Qiagen) and ampli®ed by PCR, and together with DNA from the YACs (789f2 and the adjacent 934g9, 950e2, 692c1, 955e11 and 764a1) were digested by BamHI before electrophoresis and blotting. The membrane with cDNAs was hybridized with total human DNA, YAC 789f2 and an irrelevant YAC (883H6), and the YAC membrane was hybridized with the captured cDNA clones for COAS1, COAS2 and COAS3.
Captured cDNAs were sequenced on an ALF express automatic sequencer (Amersham Pharmacia Biotech, UK) using vector primers and the Thermo Sequenase cycle sequencing kit (Amersham Pharmacia Biotech, UK). Sequence assembly and analysis was performed using the DNAstar (DNASTAR Inc.) analysis package, the Vector NTI suite (Informax Inc.) and the BLAST search engines at NCBI.
Screening of cosmid libraries
A¯ow-sorted chromosome 1 cosmid library (ICRFc112) (Nizetic et al., 1994) was screened by Southern hybridization. The library was initially screened using a pool of the three captured cDNAs as probe (Groet et al., 1998) . The following cosmids were selected and used for FISH analysis: ICRFc112K0437 (COAS1), ICRFc112N1180 (COAS2) and ICRFc112I1772 (COAS3).
Fluorescence in situ hybridization (FISH)
Normal metaphase chromosomes from peripheral leukocytes and interphase nuclei from frozen tumour tissues were prepared as described previously (Forus et al., 1998) . PCR products and cosmid DNA was labelled with biotin-14-dATP or digoxygenin-11-dUTP (Roche Biochemical) by nick translation. For each hybridization, 200 ± 500 ng of labelled DNA was prehybridized with 50 ± 100-fold excess of human Cot-1 DNA. Pretreatment of slides, hybridization and washes were done as described (Forus et al., 1998 . For detection of digoxygenin we used uorescein isothiocyanate (FITC) conjugated sheep anti-digoxygenin antibody (Roche Biochemicals) followed by FITC or ALEXA 488 labelled donkey anti sheep (Molecular Probes, The Netherlands). Detection of biotin-labelled cosmid probes was detected by avidin-conjugated Cy3 (Amersham Pharmacia Biotech, UK), whereas biotin-labelled PCR products were detected using the thyramide ampli®cation procedure (TSAIndirect (ISH), NEN Life Science Products, Boston, MA, USA). The antibodies used were avidin-Cy3 (Amersham Pharmacia Biotech, UK), FITC-labelled streptavidin (NEN) and biotinylated anti-avidin D (Vector Laboratories). Hybridized slides were examined visually using a Zeiss Axioplan microscope with ®lters for excitation of DAPI, DAPI/FITC, DAPI/Rhodamine (Cy3), and DAPI/FITC/Rhodamine (Cy3). For each probe localization of the signal was evaluated in at least 10 metaphases, and copy numbers evaluated in at least 150 nuclei. Ampli®cation levels were grouped as follows: normal (two signals); moderate (3 ± 9 signals); and high (10 or more signals).
Northern blot analysis
RNA puri®cation, electrophoresis, transfer to nylon ®lter and hybridization were as previously described (Forus et al., 1993) . Quanti®cation of the signal intensities was performed by twodimensional densitometry on a Molecular Dynamics laser densitometer. The net signal values from speci®c bands were corrected for unequal sample loading by calibration relative to the signal obtained from an 18S ribosomal RNA probe.
Dierent cDNAs and PCR products were used as probe for Northern blot hybridizations. As probe for COAS1 was used a 1 kb cDNA fragments containing the 866 bp repeat unit; for COAS2 a 495 bp PCR product enclosing the complete open reading frame; and for COAS3 a 1338 bp cDNA fragment isolated from the library screening.
